ViewRay

The MRIdian system by ViewRay has been commercially deployed worldwide and used to treat over 12,500 patients. Peer-reviewed evidence supports reduced side effects and extended survival in certain cancers by enabling precise targeting with real-time MRI guidance during radiation therapy. The technology allows for adaptive treatment plans and automated beam control to minimize exposure to healthy tissue. Clinical use includes successful treatment of tumors previously considered untreatable or difficult due to movement or proximity to critical structures. As a device/platform company rather than a drug developer, traditional clinical trial stages do not apply.